Kenshi Suzuki

Summary

Country: Japan

Publications

  1. doi request reprint Current therapeutic strategy for multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Jpn J Clin Oncol 43:116-24. 2013
  2. pmc Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo 150 8935, Japan
    Clin Exp Nephrol 16:659-71. 2012
  3. doi request reprint Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma
    Klio Konstantinou
    Department of Comprehensive Pathology, Ageing and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Br J Haematol 144:696-704. 2009
  4. ncbi request reprint IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes
    Yasunori Nakagawa
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Am J Hematol 81:824-31. 2006
  5. doi request reprint Follicular lymphoma with marked infiltration of eosinophils
    Junichi Shiraishi
    Department of Pathology, Japanese Red Cross Medical Center, Tokyo, Japan
    Pathol Int 58:701-5. 2008
  6. ncbi request reprint Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22, Hiroo, Shibuya, Tokyo, 150 8935, Japan
    Eur J Drug Metab Pharmacokinet 33:191-8. 2008
  7. ncbi request reprint [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis]
    Mizuki Ogura
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 53:710-5. 2012
  8. doi request reprint Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma
    Yu Abe
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Exp Hematol 37:956-68. 2009
  9. ncbi request reprint Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia
    Tamara Keith
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Br J Haematol 137:206-15. 2007
  10. ncbi request reprint [Increased level of KL-6 in a BJP-λ-type multiple myeloma patient with poor prognosis]
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, Japan
    Rinsho Ketsueki 53:521-5. 2012

Collaborators

Detail Information

Publications19

  1. doi request reprint Current therapeutic strategy for multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Jpn J Clin Oncol 43:116-24. 2013
    ..However, multiple myelomas are still difficult to cure and require long-term disease control. In recent years, the introduction of novel drugs (bortezomib, lenalidomide and thalidomide) has improved treatment...
  2. pmc Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo 150 8935, Japan
    Clin Exp Nephrol 16:659-71. 2012
    ..However, they are still difficult to be cured and require long-term disease control. In recent years, introduction of novel agents has changed their treatment strategies from the palliation therapy to the clinical cure...
  3. doi request reprint Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma
    Klio Konstantinou
    Department of Comprehensive Pathology, Ageing and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Br J Haematol 144:696-704. 2009
    ....
  4. ncbi request reprint IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes
    Yasunori Nakagawa
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Am J Hematol 81:824-31. 2006
    ..These findings indicate that IAP family proteins might play a role in worsening the prognosis of MM patients in association with chemotherapy-induced overexpression of MDR1 or LRP...
  5. doi request reprint Follicular lymphoma with marked infiltration of eosinophils
    Junichi Shiraishi
    Department of Pathology, Japanese Red Cross Medical Center, Tokyo, Japan
    Pathol Int 58:701-5. 2008
    ..This was a unique case of follicular lymphoma with extensive eosinophil infiltration, and to the best of the authors' knowledge this is the first such case ever reported...
  6. ncbi request reprint Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22, Hiroo, Shibuya, Tokyo, 150 8935, Japan
    Eur J Drug Metab Pharmacokinet 33:191-8. 2008
    ..These results suggest that MCFG can be administered safely to patients with liver or kidney dysfunction without adjusting the dose...
  7. ncbi request reprint [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis]
    Mizuki Ogura
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 53:710-5. 2012
    ..Further studies are required to clarify an effective MEL dose and to refine selection criteria for patients undergoing HDM/SCT...
  8. doi request reprint Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma
    Yu Abe
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Exp Hematol 37:956-68. 2009
    ....
  9. ncbi request reprint Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia
    Tamara Keith
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Br J Haematol 137:206-15. 2007
    ..These findings indicate that the bone marrow microenvironment in MDS --> OL and de novo AML differs remarkably, suggesting the different efficacy of anti-angiogenic therapy between de novo AML and leukaemia secondary to MDS...
  10. ncbi request reprint [Increased level of KL-6 in a BJP-λ-type multiple myeloma patient with poor prognosis]
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, Japan
    Rinsho Ketsueki 53:521-5. 2012
    ..For this patient, multiple myeloma with high KL-6 was refractory to chemotherapy, suggesting that new treatment strategies, including transplantation of hematopoietic stem cells, are required...
  11. doi request reprint Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma
    Thomas J Smith
    Department of Comprehensive Pathology, Ageing and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, 1 5 45 Bunkyo Ku, Tokyo, Japan
    Exp Mol Pathol 89:284-90. 2010
    ..TLR expression is highly variable among lymphoma subtypes. However, despite this some significant differences exist that may prove useful in the development of novel therapeutic strategies...
  12. ncbi request reprint [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma]
    Isao Matsuda
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 46:1293-7. 2005
    ..Two color analysis of CD38 x CD20 antigens may be necessary to investigate CD20 expression on MM cells. Rituximab may be effective for the treatment of CD20-positive MM...
  13. doi request reprint Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study
    Yasunori Nakagawa
    Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    J Infect Chemother 17:58-67. 2011
    ..BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases...
  14. doi request reprint Type AB thymoma accompanied by pure red cell aplasia and Good syndrome with CMV infection of tumor cells
    Junichi Shiraishi
    Department of Pathology, Japanese Red Cross Medical Center, Shibuya ku, Tokyo, Japan
    Pathol Int 58:489-93. 2008
    ..Several cases of Good syndrome with widespread CMV infection have been reported, but it is extremely rare for CMV-inclusion bodies to be found in tumor cells. No thymoma cases involving CMV infection of tumor cells have been reported...
  15. doi request reprint Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy
    Yasunori Nakagawa
    Department of Oncology and Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo, 150 8935, Japan
    J Infect Chemother 15:174-9. 2009
    ..At the onset of FN, they were expressed in points for evaluation. Further prospective studies are needed to determine whether these risk factors are suitable for use in actual cases...
  16. ncbi request reprint Plasma concentration of micafungin in patients with hematologic malignancies
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    J Infect Chemother 13:39-45. 2007
    ....
  17. ncbi request reprint Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL)
    Yasunori Nakagawa
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan
    Am J Hematol 78:173-80. 2005
    ..05), NAIP (P <0.05), and XIAP (P <0.05). These findings suggest that higher expression of various IAPs is associated with the chemotherapy-resistant nature of this specific type of leukemia...
  18. ncbi request reprint [Therapy of non-Hodgkin's lymphoma]
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center
    Nihon Rinsho 65:521-8. 2007
  19. ncbi request reprint Clinical implications of abnormalities of chromosomes 1 and 13 in multiple myeloma
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Acta Haematol 109:129-36. 2003
    ..02). Consequently, aggressive treatment such as early stem cell transplantation and so on is needed to improve their survival...